arrow
K

Ki Hyeong Lee

chungbuk national university college of medicine
H指数:65
被引数:4.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Quality of Life Outcomes From the Phase 3 Study of Atezolizumab + Bevacizumab and Chemotherapy ( ATTLAS , KCSG ‐ LU19 ‐04) in EGFR / ALK ‐Mutated Non–Small‐Cell Lung Cancer

来自阿替利珠单抗联合贝伐珠单抗和化疗(<scp>ATTLAS</scp>,<scp>KCSG</scp>‐<scp>LU19</scp>‐04)治疗<scp>EGFR</scp>/<scp>ALK</scp>突变非小细胞肺癌的III期研究生活质量结果

2026-11-160
PRE
Lazertinib Plus Pemetrexed and Carboplatin in Patients With EGFR-Mutant Advanced Non-Small Cell Lung Cancer after Progression on Lazertinib

拉泽替尼联合培美曲塞和卡铂用于拉泽替尼治疗后进展的<em>EGFR</em>突变晚期非小细胞肺癌患者

2026-10-080
OAAI
Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapy

LAURA研究中的患者报告结局:奥希替尼用于不可切除的III期EGFR突变非小细胞肺癌患者完成根治性放化疗后的治疗

2026-04-120
PRE
Exploratory Analyses of Patient Preferences for Atezolizumab Subcutaneous Versus Intravenous from the IMscin002 Study in Patients with Non-Small Cell Lung Cancer

IMscin002研究:非小细胞肺癌患者对阿替利珠单抗皮下给药与静脉给药的偏好探索性分析

2025-11-260
OAAI
Central nervous system outcomes of lazertinib treatment in EGFR-mutated advanced NSCLC: Pooled analysis from LASER201 and LASER301

拉泽替尼治疗EGFR突变晚期NSCLC的神经系统结局:LASER201和LASER301的合并分析

2025-09-010
PREAI
Amivantamab in Participants With Advanced NSCLC and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study

Amivantamab在晚期NSCLC和MET外显子14跳跃突变参与者中的应用: CHRYSALIS研究的最终结果

2025-05-160
PREAI
First-line nivolumab plus platinum chemotherapy and bevacizumab for advanced nonsquamous non-small cell lung cancer: A 3-year follow-up of the phase 3 randomized TASUKI-52 trial

一线纳武利尤单抗联合铂类化疗和贝伐珠单抗治疗晚期非鳞非小细胞肺癌:TASUKI-52 III期随机试验3年随访

2025-03-010
PRE
Clinical Outcomes of Maintenance Durvalumab After Definitive Concurrent Chemoradiotherapy in Unresectable Locally Advanced Stage III NSCLC According to EGFR and ALK Status: Korean Cancer Study Group LU-22-18

根据EGFR和ALK状态,不可切除的局部晚期III期NSCLC在确定性同步放化疗后维持Durvalumab的临床结局: 韩国癌症研究小组LU-22-18

2024-12-010
OA
Patient satisfaction and preference for atezolizumab subcutaneous (atezo SC) by body mass index (BMI) or race (Asian vs non-Asian) from IMscin001 and IMscin002

患者满意度及对阿替利珠单抗皮下注射(atezo SC)的偏好,按体重指数(BMI)或种族(亚洲人与非亚洲人)分组,数据来源于IMscin001和IMscin002研究。

2024-12-010
PRE
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer

局限期小细胞肺癌放化疗后的Durvalumab

2024-10-108
PRE
Updated overall survival and ctDNA analysis in patients with EGFR T790M-positive advanced non-small cell lung cancer treated with lazertinib in the phase 1/2 LASER201 study

1/2期LASER201研究中使用拉泽替尼治疗的EGFR T790M-positive晚期非小细胞肺癌患者的更新的总生存期和ctDNA分析

2024-10-080
OAAI
ABBV-400, a c-Met proteinetargeting antibody-drug conjugate (ADC), in patients (pts) with advanced gastric/gastroesophageal junction adenocarcinoma (GEA): Results from a phase I study

ABBV-400,一种靶向c-Met蛋白的抗体偶联药物(ADC),用于晚期胃/胃食管结合部腺癌(GEA)患者(pts)的I期研究结果

2024-09-012
PRE
Amivantamab in wild-type advanced non-small cell lung cancer after disease progression on checkpoint inhibition and chemotherapy: Results from the phase 1b CHRYSALIS study
2024-04-050
PRE
Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC

研究总结: 奥希替尼治疗EGFR突变非小细胞肺癌的总生存期

2024-03-110
OAAI
Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC

不可切除的III期NSCLC同步放化疗后Durvalumab的症状性肺炎

2024-03-013
OA